Clinical Trial Update: Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating long-term safety, pharmacodynamics, and exploratory efficacy of GZ/SAR402671 in treatment-naïve adult male Fabry disease patients has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• GZ/SAR402671

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-12-09